Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in Elderly Advanced Non-squamous NSCLC Without Systemic Chemotherapy
NCT03778853Phase 4Unknown
- Sponsor
- Lanzhou University
- Start
- Jan 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of anlotinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Lanzhou University. Primary endpoint: Progression-Free Survival up to 24 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03778853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03778853.